Drugs / MB05
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05121246 | Jun 2022 → Mar 2023 | — | mAbxience Research S.L. | Completed | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MB05 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05121246 ↗ |
| Route | Intramuscular | “administered as intramuscular injection” NCT05121246 ↗ |